Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

COCP Cocrystal Pharma Inc

Price (delayed)

$1.63

Market cap

$16.58M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.57

Enterprise value

$11.23M

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. ...

Highlights
Cocrystal Pharma's EPS has increased by 9% from the previous quarter and by 4.8% YoY
Cocrystal Pharma's net income has increased by 9% from the previous quarter and by 5% YoY
The company's equity has shrunk by 68% YoY and by 23% QoQ
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ

Key stats

What are the main financial stats of COCP
Market
Shares outstanding
10.17M
Market cap
$16.58M
Enterprise value
$11.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.27
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$16.06M
Net income
-$15.85M
EBIT
-$16.18M
EBITDA
-$16.07M
Free cash flow
-$14.92M
Per share
EPS
-$1.57
EPS diluted
-$1.57
Free cash flow per share
-$1.47
Book value per share
$0.72
Revenue per share
$0
TBVPS
$1.05
Balance sheet
Total assets
$10.66M
Total liabilities
$3.36M
Debt
$1.73M
Equity
$7.3M
Working capital
$6.9M
Liquidity
Debt to equity
0.24
Current ratio
4.57
Quick ratio
3.67
Net debt/EBITDA
0.33
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-102.4%
Return on equity
-135.1%
Return on invested capital
-551.5%
Return on capital employed
-185.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

COCP stock price

How has the Cocrystal Pharma stock price performed over time
Intraday
0%
1 week
-4.68%
1 month
10.51%
1 year
-36.82%
YTD
-19.31%
QTD
14.79%

Financial performance

How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.06M
Net income
-$15.85M
Gross margin
N/A
Net margin
N/A

COCP financials

The operating income has grown by 10% from the previous quarter and by 9% YoY
Cocrystal Pharma's net income has increased by 9% from the previous quarter and by 5% YoY

Price vs fundamentals

How does COCP's price correlate with its fundamentals

COCP Price vs fundamentals

COCP Earnings waterfall

COCP Price vs fair value

Growth

What is Cocrystal Pharma's growth rate over time

COCP growth chart

Valuation

What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
2.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Valuation vs average

Price to earnings (P/E)

Cocrystal Pharma's EPS has increased by 9% from the previous quarter and by 4.8% YoY

Price to book (P/B)

The stock's P/B is 106% above its 5-year quarterly average of 1.1 and 34% above its last 4 quarters average of 1.7
The company's equity has shrunk by 68% YoY and by 23% QoQ

Price to sales (P/S)

Efficiency

How efficient is Cocrystal Pharma business performance
Cocrystal Pharma's ROE has plunged by 131% YoY and by 20% from the previous quarter
The ROA has plunged by 94% YoY and by 14% from the previous quarter
COCP's return on invested capital is up by 12% year-on-year and by 2.5% since the previous quarter

Dividends

What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for COCP.

Financial health

How did Cocrystal Pharma financials performed over time

Assets vs liabilities

The total assets has plunged by 60% YoY and by 21% from the previous quarter
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ

Debt vs equity

The debt is 76% less than the equity
COCP's debt to equity has soared by 200% YoY and by 26% QoQ
The company's equity has shrunk by 68% YoY and by 23% QoQ

Balance sheet

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.